TY - JOUR
T1 - Challenges for African swine fever vaccine development—“… perhaps the end of the beginning.”
AU - Rock, D. L.
N1 - Funding Information:
I am grateful to Edan Tulman and Gustavo Delhon for manuscript suggestions and review comments. I thank members of our current ASF Research Group – G. Burmakina, A. Malogolovkin, E. Tulman, G. Delhon, G. Kutish and D. Kolbasov as well as past members of the African Swine Fever Research Group, Plum Island Animal Disease Center, ARS USDA, for their efforts and research accomplishments on ASF. A very special thanks to Dr. Roger Breeze for his interest, encouragement and unwavering support of ASF research. Our research work is supported by the National Pork Board (grants: 12-106 and 13-102) the USDA National Institute of Food and Agriculture (grant: 2013-67015-21335) and the Russian Science Foundation (grant: 16-16-00090).
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2017/7
Y1 - 2017/7
N2 - African swine fever (ASF), an acute, viral hemorrhagic disease in domestic swine with mortality rates approaching 100%, is arguably the most significant emerging disease threat for the swine industry worldwide. Devastating ASF outbreaks and continuing epidemic in the Caucasus region and Russia (2007–to date) highlight significance of this disease threat. There is no vaccine for ASF, thus leaving animal slaughter the only effective disease control option. It is clear, however, that vaccination is possible since protection against reinfection with the homologous strain of African swine fever virus (ASFV) has been clearly demonstrated. Vaccine development has been hindered by large gaps in knowledge concerning ASFV infection and immunity, the extent of ASFV strain variation in nature and the identification of viral proteins (protective antigens) responsible for inducing protective immune responses in the pig. This review focuses on the challenges surrounding ASF vaccine design and development, with an emphasis on existing knowledge gaps.
AB - African swine fever (ASF), an acute, viral hemorrhagic disease in domestic swine with mortality rates approaching 100%, is arguably the most significant emerging disease threat for the swine industry worldwide. Devastating ASF outbreaks and continuing epidemic in the Caucasus region and Russia (2007–to date) highlight significance of this disease threat. There is no vaccine for ASF, thus leaving animal slaughter the only effective disease control option. It is clear, however, that vaccination is possible since protection against reinfection with the homologous strain of African swine fever virus (ASFV) has been clearly demonstrated. Vaccine development has been hindered by large gaps in knowledge concerning ASFV infection and immunity, the extent of ASFV strain variation in nature and the identification of viral proteins (protective antigens) responsible for inducing protective immune responses in the pig. This review focuses on the challenges surrounding ASF vaccine design and development, with an emphasis on existing knowledge gaps.
KW - ASF vaccine, protective antigens
KW - ASF, protective immunity
KW - African swine fever
UR - http://www.scopus.com/inward/record.url?scp=85002249000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002249000&partnerID=8YFLogxK
U2 - 10.1016/j.vetmic.2016.10.003
DO - 10.1016/j.vetmic.2016.10.003
M3 - Article
C2 - 27756505
AN - SCOPUS:85002249000
SN - 0378-1135
VL - 206
SP - 52
EP - 58
JO - Veterinary Microbiology
JF - Veterinary Microbiology
ER -